---
reference_id: "PMID:32130918"
title: Pathogenic FBN1 Genetic Variation and Aortic Dissection in Patients With Marfan Syndrome.
authors:
- Milleron O
- Arnoult F
- Delorme G
- Detaint D
- Pellenc Q
- Raffoul R
- Tchitchinadze M
- Langeois M
- Guien C
- Beroud C
- Ropers J
- Hanna N
- Arnaud P
- Gouya L
- Boileau C
- Jondeau G
journal: J Am Coll Cardiol
year: '2020'
doi: 10.1016/j.jacc.2019.12.043
content_type: abstract_only
---

# Pathogenic FBN1 Genetic Variation and Aortic Dissection in Patients With Marfan Syndrome.
**Authors:** Milleron O, Arnoult F, Delorme G, Detaint D, Pellenc Q, Raffoul R, Tchitchinadze M, Langeois M, Guien C, Beroud C, Ropers J, Hanna N, Arnaud P, Gouya L, Boileau C, Jondeau G
**Journal:** J Am Coll Cardiol (2020)
**DOI:** [10.1016/j.jacc.2019.12.043](https://doi.org/10.1016/j.jacc.2019.12.043)

## Content

1. J Am Coll Cardiol. 2020 Mar 3;75(8):843-853. doi: 10.1016/j.jacc.2019.12.043.

Pathogenic FBN1 Genetic Variation and Aortic Dissection in Patients With 
Marfan Syndrome.

Milleron O(1), Arnoult F(2), Delorme G(1), Detaint D(1), Pellenc Q(3), Raffoul 
R(4), Tchitchinadze M(1), Langeois M(1), Guien C(5), Beroud C(5), Ropers J(6), 
Hanna N(7), Arnaud P(8), Gouya L(9), Boileau C(10), Jondeau G(11).

Author information:
(1)Centre de référence pour le syndrome de Marfan et apparentés, VASCERN HTAD 
European Reference Center, AP-HP, Hôpital Bichat, Paris, France.
(2)Centre de référence pour le syndrome de Marfan et apparentés, VASCERN HTAD 
European Reference Center, AP-HP, Hôpital Bichat, Paris, France; Service des 
explorations fonctionnelles AP-HP, Hôpital Bichat, Paris, France.
(3)Service de chirurgie vasculaire AP-HP, Hôpital Bichat, Paris, France.
(4)Service de chirurgie cardiaque AP-HP, Hôpital Bichat, Paris, France.
(5)Aix Marseille Université, INSERM, MMG, Bioinformatics & Genetics, Marseille, 
France.
(6)Unité De Recherche Clinique, AP-HP, Pitié Salpêtrière-Charles Foix, Paris, 
France.
(7)Département de génétique moléculaire AP-HP, Hôpital Bichat, Paris, France; 
INSERM U1148, LVTS, Hôpital Bichat, Paris, France.
(8)Département de génétique moléculaire AP-HP, Hôpital Bichat, Paris, France; 
INSERM U1148, LVTS, Hôpital Bichat, Paris, France; Université de Paris, Paris, 
France.
(9)Centre de référence pour le syndrome de Marfan et apparentés, VASCERN HTAD 
European Reference Center, AP-HP, Hôpital Bichat, Paris, France; Université de 
Paris, Paris, France.
(10)Centre de référence pour le syndrome de Marfan et apparentés, VASCERN HTAD 
European Reference Center, AP-HP, Hôpital Bichat, Paris, France; Département de 
génétique moléculaire AP-HP, Hôpital Bichat, Paris, France; INSERM U1148, LVTS, 
Hôpital Bichat, Paris, France; Université de Paris, Paris, France.
(11)Centre de référence pour le syndrome de Marfan et apparentés, VASCERN HTAD 
European Reference Center, AP-HP, Hôpital Bichat, Paris, France; INSERM U1148, 
LVTS, Hôpital Bichat, Paris, France; Université de Paris, Paris, France. 
Electronic address: guillaume.jondeau@aphp.fr.

Comment in
    J Am Coll Cardiol. 2020 Mar 3;75(8):854-856. doi: 
10.1016/j.jacc.2019.12.042.

BACKGROUND: Aortic risk has not been evaluated in patients with Marfan syndrome 
and documented pathogenic variants in the FBN1 gene.
OBJECTIVES: This study sought to describe aortic risk in a population with 
Marfan syndrome with pathogenic variants in the FBN1 gene as a function of 
aortic root diameter.
METHODS: Patients carrying an FBN1 pathogenic variant who visited our reference 
center at least twice were included, provided they had not undergone aortic 
surgery or had an aortic dissection before their first visit. Aortic events 
(aortic surgery or aortic dissection) and deaths were evaluated during the 2 
years following each patient visit. The risk was calculated as the number of 
events divided by the number of years of follow-up.
RESULTS: A total of 954 patients were included (54% women; mean age 23 years). 
During follow-up (9.1 years), 142 patients underwent prophylactic aortic root 
surgery, 5 experienced type A aortic dissection, and 12 died (noncardiovascular 
causes in 3, unknown etiology in 3, post-operative in 6). When aortic root 
diameter was <50 mm, risk for proven type A dissection (0.4 events/1,000 
patient-years) and risk for possible aortic dissection (proven aortic dissection 
plus death of unknown cause, 0.7 events/1,000 patients-years) remained low in 
this population that was treated according to guidelines. Three type A aortic 
dissections occurred in this population during the 8,594 years of follow-up, 
including 1 in a patient with a tubular aortic diameter of 50 mm, but none in 
patients with a family history of aortic dissection. The risk for type B aortic 
dissection in the same population was 0.5 events/1,000 patient-years.
CONCLUSIONS: In patients with FBN1 pathogenic variants who receive beta-blocker 
therapy and who limit strenuous exercise, aortic risk remains low when maximal 
aortic diameter is <50 mm. The risk of type B aortic dissection is close to the 
remaining risk of type A aortic dissection in this population, which underlines 
the global aortic risk.

Copyright © 2020 American College of Cardiology Foundation. Published by 
Elsevier Inc. All rights reserved.

DOI: 10.1016/j.jacc.2019.12.043
PMID: 32130918 [Indexed for MEDLINE]